Tudor Investment Corp ET AL Buys Shares of 17,120 Alkermes plc (NASDAQ:ALKS)

Tudor Investment Corp ET AL purchased a new position in Alkermes plc (NASDAQ:ALKS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 17,120 shares of the company's stock, valued at approximately $492,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALKS. Venturi Wealth Management LLC bought a new position in shares of Alkermes during the fourth quarter valued at $25,000. EverSource Wealth Advisors LLC boosted its position in Alkermes by 106.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company's stock worth $47,000 after purchasing an additional 842 shares during the last quarter. Blue Trust Inc. boosted its position in Alkermes by 2,231.5% in the fourth quarter. Blue Trust Inc. now owns 1,702 shares of the company's stock worth $49,000 after purchasing an additional 1,629 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Alkermes by 558.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company's stock valued at $85,000 after buying an additional 2,502 shares in the last quarter. Finally, Cornerstone Investment Partners LLC purchased a new position in shares of Alkermes during the 4th quarter valued at about $203,000. Hedge funds and other institutional investors own 95.21% of the company's stock.

Insider Activity at Alkermes

In other news, EVP Craig C. Hopkinson sold 144,419 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the completion of the sale, the executive vice president now owns 57,875 shares in the company, valued at approximately $2,056,298.75. The trade was a 71.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.40% of the stock is currently owned by corporate insiders.

Alkermes Trading Up 3.8%

ALKS stock traded up $1.14 during midday trading on Monday, reaching $31.27. The stock had a trading volume of 1,274,066 shares, compared to its average volume of 1,773,838. Alkermes plc has a 52-week low of $22.90 and a 52-week high of $36.45. The company's fifty day simple moving average is $30.93 and its 200 day simple moving average is $30.57. The company has a market cap of $5.16 billion, a price-to-earnings ratio of 14.41, a price-to-earnings-growth ratio of 2.20 and a beta of 0.51.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). The business had revenue of $306.51 million for the quarter, compared to analysts' expectations of $307.53 million. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. The firm's revenue for the quarter was down 12.6% on a year-over-year basis. During the same quarter last year, the company earned $0.43 earnings per share. Sell-side analysts predict that Alkermes plc will post 1.31 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. UBS Group reissued a "sector perform" rating on shares of Alkermes in a research note on Monday, April 28th. StockNews.com downgraded Alkermes from a "strong-buy" rating to a "buy" rating in a research note on Monday, May 5th. Royal Bank of Canada boosted their target price on Alkermes from $39.00 to $40.00 and gave the company a "sector perform" rating in a research report on Friday, May 2nd. Robert W. Baird boosted their target price on Alkermes from $38.00 to $41.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Finally, HC Wainwright reissued a "neutral" rating on shares of Alkermes in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $38.33.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.